GSK to Acquire Nuvalent in $10.6B Deal to Expand Oncology Portfolio

London, June 9, 2026 (GSK) -- GSK has entered an agreement to acquire Nuvalent in a transaction valued at $10.6 billion. The acquisition adds late-stage targeted oncology assets focused on lung cancer and expands GSK’s precision medicine capabilities. The deal is intended to accelerate growth in oncology and strengthen the company’s long-term pipeline strategy.

Read full article here.